Rare cancers (general) trials

AI-generated summary

TCF-001 TRACK (Target Rare Cancer Knowledge) Study is being studied. Conditions: Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site • Eligibility: INCLUSION CRITERIA * Provision of signed and dated informed consent form. * Stated willingness to comply with all study related blood draws and assessments for the duration of…. Goal: This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results. Phase/Status/Sponsor: Unknown phase; RECRUITING; TargetCancer Foundation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma is being studied. Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor +5 • Eligibility: Inclusion Criteria: All Patients * Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or…. Goal: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cellectar Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Immunotherapy in Rare Cancers Under InvesTigation is being studied. Conditions: Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm +1 • Eligibility: Inclusion Criteria: 1. Signed Written Informed Consent * Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the…. Goal: The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups: 1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded) 2. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Olivia Newton-John Cancer Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy is being studied. Conditions: Germ Cell Tumor, Sex Cord Stromal Tumor, Malignant Non-epithelial Ovarian Tumors • Eligibility: Inclusion Criteria: * Age\> 18 years; * Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;…. Goal: While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remission of rare ovarian cancer remain poorly explored. The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Centre Francois Baclesse.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase II trial tests the combination of nivolumab and ipilimumab for people with rare cancers. Participants are grouped into three tumour streams: upper GI malignancies, neuroendocrine tumours, and rare gynecologic tumours. The study aims to see whether this immunotherapy combo can improve progression-free survival and overall survival, and to assess safety. Eligible adults must have confirmed disease in these groups and measurable disease, and must not have had prior combination PD-1/PD-L1 and CTLA-4 therapy; key exclusions include active brain metastases unless treated and stable, autoimmune disease, certain infections, pregnancy, and imprisonment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.